Literature DB >> 8597746

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary.

C W Olanow, J H Godbold, W Koller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8597746      PMCID： PMC2350527     

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Designs for group sequential tests.

Authors:  T R Fleming; D P Harrington; P C O'Brien
Journal:  Control Clin Trials       Date:  1984-12

2.  Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued.

Authors:  H Przuntek; D Welzel; E Blümner; W Danielczyk; H Letzel; H J Kaiser; P H Kraus; P Riederer; D Schwarzmann; H Wolf
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.

Authors:  A J Lees
Journal:  BMJ       Date:  1995-12-16

4.  The effect of deprenyl and levodopa on the progression of Parkinson's disease.

Authors:  C W Olanow; R A Hauser; L Gauger; T Malapira; W Koller; J Hubble; K Bushenbark; D Lilienfeld; J Esterlitz
Journal:  Ann Neurol       Date:  1995-11       Impact factor: 10.422
  4 in total
  2 in total

1.  Mortality associated with selegiline in Parkinson's disease. What do the available data mean?

Authors:  Y Mizuno; T Kondo
Journal:  Drug Saf       Date:  1997-05       Impact factor: 5.228

2.  Ogg1 null mice exhibit age-associated loss of the nigrostriatal pathway and increased sensitivity to MPTP.

Authors:  Fernando Cardozo-Pelaez; Monica Sanchez-Contreras; Andrew B C Nevin
Journal:  Neurochem Int       Date:  2012-06-26       Impact factor: 3.921
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.